Abbott gets nod from DCGI for once-a-day formulation ‘Ivabradine’

03 Sep 2020 Evaluate

Abbott has received approval from the Drugs Controller General of India (DCGI) for its once-a-day formulation, Ivabradine, used for treatment of chronic heart failure and chronic stable angina. The company plans to launch Ivabradine prolonged release tablets in the Indian market in the coming weeks.

Abbott India is healthcare company that discovers, develops, manufactures and markets innovative products and services.

Abbott India Share Price

26476.45 6.50 (0.02%)
16-Feb-2026 14:36 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1699.95
Dr. Reddys Lab 1269.00
Cipla 1352.20
Zydus Lifesciences 909.95
Lupin 2221.40
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×